Webcast Alert: Oscient Pharmaceuticals to Participate in the BIO CEO & Investor Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (NASDAQ:OSCI) will participate in the BIO CEO & Investor Conference on Wednesday, February 13, 2008 in New York City. Hosted by the Biotechnology Industry Organization (BIO), the 10^th Annual BIO CEO & Investor Conference will feature company presentations, one-on-one meetings and educational panel sessions attended by institutional investors, industry analysts, venture capitalists and investment bankers.

The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company; highlight details on the recent market performance of ANTARA^® (fenofibrate) capsules and FACTIVE^® (gemifloxacin mesylate) tablets in the U.S.; and discuss the Company's recently announced results for fiscal year 2007, in which Oscient recorded $80.0 million in revenues.

What:	10th Annual BIO CEO & Investor Conference
When:	February 13, 2008 at 2:45 pm Eastern Time
How:	The presentation will be webcast through the Company's
	website at www.oscient.com.
Contact:	Christopher Taylor, 781-398-2466
	Sarah Emond, 781-398-2544

An archive of the webcast will also be available for 90 days.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States: ANTARA^® (fenofibrate) capsules, a cardiovascular product and FACTIVE^® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a nationwide sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists. The Company also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium difficile-associated disease (CDAD).

For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com. For a complete description of the risks associated with our business please refer to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2007 and in other filings that we may make with the Securities and Exchange Commission from time to time.